CollPlant Biotechnologies (CLGN) EBITDA Margin (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted EBITDA Margin of 4267.12% for Q1 2026, up 18.72% on a QoQ basis from 5250.0% in Q4 2025, and down 418693.0% year-over-year from N/an in Q1 2025.
CollPlant Biotechnologies (CLGN) EBITDA Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' EBITDA Margin history runs 10 years deep, the most recent figure standing at 4267.12% for Q1 2026.
- Quarterly EBITDA Margin fell 418693.0% year-over-year to 4267.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1695.12% (down 146219.0% YoY) and the FY2025 annual result came in at 484.31%, up 286540.0% from the prior year.
- EBITDA Margin was 4267.12% for Q1 2026 at CollPlant Biotechnologies, up from 5250.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 4417.35% in Q1 2024 and bottomed at 113550.0% in Q3 2024.
- A 5-year average of 8843.21% and a median of 2059.08% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin slumped 11354999 bps — and 2025, when it jumped 10899545 bps.
- CollPlant Biotechnologies' EBITDA Margin stood at 8062.07% in 2022, then jumped by 79 bps to 1694.98% in 2023, then plunged by 43 bps to 2423.17% in 2024, then slumped by 117 bps to 5250.0% in 2025, then rose by 19 bps to 4267.12% in 2026.
- Business Quant data shows CLGN's EBITDA Margin at 4267.12% in Q1 2026, 5250.0% in Q4 2025, and 4554.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 23.02% |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | -4,267.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -5,250.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -2,423.17% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -1,694.98% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -8,062.07% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -1,227.10% |
| Sep 30, 2021 | -2,210.00% |
| Jun 30, 2021 | -443.27% |
| Mar 31, 2021 | 69.14% |